Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | SGK1 | O00141 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13628713 | 0.91 | SGK1 (0.64) | MAPTGAATHRBALDH1A1SMN1; SMN2 | |
| SCHEMBL13637834 | 0.90 | SGK1 (0.59) | MAPTGAATHRBALDH1A1SMN1; SMN2 | |
| SCHEMBL13628724 | 0.87 | LMNA (0.56) | MAPTGAATHRBALDH1A1SMN1; SMN2 | |
| SCHEMBL13628735 | 0.83 | LMNA (0.76) | MAPTGAATHRBALDH1A1SMN1; SMN2 | |
| SCHEMBL13628763 | 0.81 | SGK1 (0.63) | MAPTALDH1A1KDM4ERAB9ASGK1 | |
| SCHEMBL13628702 | 0.81 | SGK1 (0.63) | MAPTALDH1A1SMN1; SMN2KDM4ERAB9A | |
| SCHEMBL13628792 | 0.81 | ALDH1A1 (0.58) | MAPTTHRBALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL13628758 | 0.81 | SGK1 (0.59) | MAPTALDH1A1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL4559373 | 0.80 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL4559372 | 0.80 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619115-B2 | Ortho-substituted N'-benzylidene-(3-hydroxyphenyl)acethydrazides | MERCK PATENT GMBH (DE) | 2009-11-17 | — | — | US | disclosed |
| US-7619115-B2 | Ortho-substituted N'-benzylidene-(3-hydroxyphenyl)acethydrazides | MERCK PATENT GMBH (DE) | 2009-11-17 | — | — | US | disclosed |
| US-20080032983-A1 | Such as N'-[1-(2-ethyl-4,6-dihydroxyphenyl)meth-(E)-ylidene]-(3-hydroxyphenyl)acetohydrazide which are serum glucocoriticoid kinase inhibitors; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular and kidney diseases, fibrosis and inflammation | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032983-A1 | Such as N'-[1-(2-ethyl-4,6-dihydroxyphenyl)meth-(E)-ylidene]-(3-hydroxyphenyl)acetohydrazide which are serum glucocoriticoid kinase inhibitors; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular and kidney diseases, fibrosis and inflammation | GRK4, SGK1, SGK2 | MAPT 4540/4885GAA 1627/4885THRB 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.